Cochrane Abstracts
Eslicarbazepine acetate monotherapy for epilepsy
Abstract
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the efficacy and tolerability of eslicarbazepine acetate (ESL) monotherapy for focal onset seizures or generalised tonic‐clonic epilepsy in children and adults.
Author(s)
Xian‐Chao Chang, Hu Yu, Xiao‐Dan Zhang, Yi Wang, Wen‐Ke Hong, Dong‐Xing Wang
Reviewer's Conclusions
Citation
"Eslicarbazepine Acetate Monotherapy for Epilepsy." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy_New.
Eslicarbazepine acetate monotherapy for epilepsy. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy_New. Accessed May 15, 2025.
Eslicarbazepine acetate monotherapy for epilepsy. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy_New
Eslicarbazepine Acetate Monotherapy for Epilepsy [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 May 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Eslicarbazepine acetate monotherapy for epilepsy
ID - 437871
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy_New
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
